Skip to main content

Table 1 Characteristics of TCGA patients diagnosed with high-grade serous ovarian carcinoma

From: Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity

 

Chemo-sensitive

Chemo-resistant

p-value

No. of patients

97

38

 

FIGO Stage

  

P = 0.2011

 II

9 (9.3)

1 (2.6)

 

 III

77 (79.4)

35 (92.1)

 

 IV

11 (11.3)

2 (5.3)

 

WHO Grade

  

P = 0.6123

 2

15 (15.5)

4 (10.5)

 

 3

81 (83.5)

33(86.8)

 

 Unknown

1 (1.0)

1(2.6)

 

Residual disease

  

P = 0.0708

 No Macroscopic disease

27 (27.8)

5 (13.2)

 

 1–10 mm

39 (40.2)

23 (60.5)

 

 11–20 mm

7 (7.2)

2 (5.3)

 

  > 20 mm

16 (16.5)

6 (15.8)

 

 NA

8 (8.2)

2 (5.3)

 

 Progression Free Survival(median, mons)

19.91 (3.3–87)

9.185 (2.3–15.2)

P < 0.0001

 Overall Survival (median, mons)

41.03 (8.8–125.6)

32.835 (6.7–66)

P = 0.0047